

Published in final edited form as:

Diabetes. 2004 February ; 53(0 1): S186–S189.

β -Cell Calcium-Independent Group VIA Phospholipase A₂ (iPLA₂ β):

Tracking iPLA₂ β Movements in Response to Stimulation With Insulin Secretagogues in INS-1 Cells

Shunzhong Bao¹, Chun Jin¹, Sheng Zhang¹, John Turk¹, Zhongmin Ma², and Sasanka Ramanadham¹

¹Mass Spectrometry Resource, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri

²Division of Experimental Diabetes and Aging, Mount Sinai School of Medicine, New York, New York

Abstract

Evidence that group VIA cytosolic calcium-independent phospholipase A₂ (iPLA₂ β) participates in β -cell signal transduction includes the observations that inhibition of iPLA₂ β with the bromoenol lactone suicide substrate suppresses glucose-stimulated insulin secretion and that overexpression of iPLA₂ β amplifies insulin secretory responses in INS-1 insulinoma cells. Immunofluorescence analyses also reveal that iPLA₂ β accumulates in the perinuclear region of INS-1 cells stimulated with glucose and forskolin. To characterize this phenomenon further, iPLA₂ β was expressed as a fusion protein with enhanced green fluorescent protein (EGFP) in INS-1 cells so that movements of iPLA₂ β are reflected by changes in the subcellular distribution of green fluorescence. Stimulation of INS-1 cells overexpressing iPLA₂ β -EGFP induced greater insulin secretion and punctate accumulation of iPLA₂ β -EGFP fluorescence in the perinuclear region. To determine the identity of organelles with which iPLA₂ β might associate, colocalization of green fluorescence with fluorophores associated with specific trackers targeted to different subcellular organelles was examined. Such analyses reveal association of iPLA₂ β -EGFP fluorescence with the ER and Golgi compartments. Arachidonate-containing plasmenylethanolamine phospholipid species are abundant in β -cell endoplasmic reticulum (ER) and are excellent substrates for iPLA₂ β . Arachidonic acid produced by iPLA₂ β -catalyzed hydrolysis of their substrates induces release of Ca²⁺ from ER stores—an event thought to participate in glucose-stimulated insulin secretion.

Phospholipase A₂ (PLA₂) is a diverse group of enzymes that catalyze hydrolysis of the *sn*-2 substituent from glycerophospholipid substrates to yield a free fatty acid and a 2-lysophospholipid (1,2). Among the PLA₂s is an 84-kDa cytosolic PLA₂ that does not require Ca²⁺ for catalysis and is designated group VIA cytosolic calcium-independent phospholipase A₂ (iPLA₂ β) (3–5).

A role for iPLA₂ β in signal transduction in insulin-secreting β -cells is suggested by the observations that inhibition of iPLA₂ β activity with the bromoenol lactone (BEL) suicide

© 2004 by the American Diabetes Association.

Address correspondence and reprint requests to Sasanka Ramanadham, Washington University School of Medicine, Department of Medicine, Box 8127, 660 S. Euclid Ave., St. Louis, MO 63110. sramanad@im.wustl.edu.

This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from Les Laboratoires Servier.

substrate of iPLA₂β suppresses insulin secretion, and overexpression of iPLA₂β amplifies glucose- and forskolin-stimulated insulin secretion from pancreatic islets and INS-1 insulinoma cells (6,7). Stimulation of iPLA₂β-overexpressing INS-1 cells with cAMP-elevating agents also induces translocation of iPLA₂β to the perinuclear region (7). This is of interest because glucose promotes both β-cell insulin secretion and proliferation, and glucose-induced INS-1 cell mitogenesis is cAMP dependent (8). To characterize iPLA₂β subcellular movements further, we developed INS-1 cell lines that overexpress iPLA₂β as a fusion protein with enhanced green fluorescent protein (EGFP) so that green fluorescence associated with EGFP reflects the location of iPLA₂β. Simultaneous monitoring of fluorescence associated with various tracking molecules allowed us to identify specific subcellular organelles with which iPLA₂β associates when cells are stimulated.

RESEARCH DESIGN AND METHODS

Preparation of a construct for expressing iPLA₂β as a fusion protein with EGFP and selection of stably transfected clones

Full-length iPLA₂β cDNA was amplified by PCR using the following primer set: sense, 5′ AGCTTCGAATTCATGCAGTTCTTTGGACGC-3, and antisense, 5′-TTCGATATCGGGAGATAGCAGCAGCTGG-3′. The amplified full-length iPLA₂β from the pMSCV-neo-iPLA₂β constructs were then subcloned into the pEGFP-N2 (Clontech, Palo Alto, CA) after the immediate early promoter of cytomegalovirus major and before EGFP coding sequences in the same code-reading frame with EGFP. The EGFP-N2 control vector and the construct encoding iPLA₂β-EGFP (FPN2) fusion protein were transfected into INS-1 cells with a Gene PORTER transfection system according to the manufacturer's instructions (Gene Therapy Systems, San Diego, CA). Stably transfected clones were selected using G418 (0.4 mg/ml). Stably transfected cells obtained with EGFP-N2 control vector and FPN2 construct are designed as N2 cells and FPN2 cells, respectively.

Preparation of INS-1 cell subcellular fractions and iPLA₂β enzymatic activity assay

INS-1 cells were washed with PBS and then detached by trituration. Subcellular fractions were prepared, and iPLA₂β activity in aliquots of the fractions (25 μg protein) was assayed and quantitated, as previously described (6).

Immunoblotting analyses of iPLA₂β protein

Western blot analyses were performed with INS-1 subcellular fractions, as previously described (6). The fusion protein was visualized by enhanced chemiluminescence after incubation with primary antibody, anti-green fluorescent protein (GFP) (IgG2α, 0.0002 μg/μl), or anti-iPLA₂β (0.0015 μg/μl) and then the appropriate secondary antibody.

Insulin secretion

Cells were seeded in 24-well plates and allowed to proliferate to confluency. Insulin secretion in response to glucose (0–10 mmol/l) without or with forskolin (2.5 μmol/l) was determined, as described previously (9).

Subcellular organelle tracking

To identify subcellular organelles with which iPLA₂β protein might be associated, EGFP fluorescence (fluorescein isothiocyanate [FITC], green) and fluorescence associated with various organelle markers were monitored in the FPN2-overexpressing cells, as described below. Golgi Tracker (BODIPY TR ceramide) was prepared according to the manufacturer's instructions (Molecular Probes, Eugene, OR). Cells were first incubated (4°C) with 5 μmol/l ceramide-BSA for 30 min and then washed and incubated (37°C, 1 h) in

culture medium containing no glucose and 0.1% BSA. The cells were then incubated (37°C) in medium supplemented with 2 mmol/l glucose and 2.5 μ mol/l forskolin for up to 1 h. After various intervals, fluorescent signal from EGFP (FITC) and Golgi Tracker (rhodamine) were monitored.

For tracking of ER, mitochondria, or plasma membrane, cells were first washed and then incubated (37°C, 1 h) in medium containing no glucose and 0.1% BSA. That medium was then replaced with medium containing 2 mmol/l glucose and 2.5 μ mol/l forskolin for up to 1 h. The ER tracker (Blue-White DPX, 600 nmol/l) or mitochondrial tracker (Deep Red 633, 100 nmol/l) was added during the final 30 min of incubation. The plasma membrane tracker (DiI D-282, 0.50 μ mol/l) was added during the final 20 min of incubation. After various intervals, signals from these fluorophores were monitored.

RESULTS

Immunoblotting analyses of expression of the EGFP fusion protein in INS-1 cells

To demonstrate that transfection of INS-1 cells with the vector containing the iPLA₂ β -EGFP construct causes overexpression of the fusion protein, cytosolic and membrane fractions were prepared from transfected INS-1 cells. Proteins in these fractions were analyzed by SDS-PAGE and transferred onto polyvinylidene difluoride membranes that were then used in immunoblotting analyses with antibodies directed against EGFP (Fig. 1A) or iPLA₂ β (Fig. 1B). Subcellular fractions prepared from cells transfected with the EGFP vector (N2) alone express only the EGFP-immunoreactive bands of 26 kDa (Fig. 1A, lanes 2 and 4). Transfection with the iPLA₂ β -EGFP fusion protein vector (FPN2) causes expression in both the cytosol and membrane fractions of an EGFP-immunoreactive protein with a molecular weight of 110–115 kDa (Fig. 1A, lanes 1 and 3) that represents full-length iPLA₂ β as a fusion protein. A second EGFP-immunoreactive band with a molecular weight of 90–95 kDa is also observed in cytosol of FPN2 transfected cells (Fig. 1A, lane 1). This molecular weight corresponds to an iPLA₂ β product of β 65–70 kDa plus the 26-kDa EGFP. Immunoblotting analyses with iPLA₂ β antibody (Fig. 1B) yield results similar to those observed with the GFP antibody. An iPLA₂ β -immunoreactive protein corresponding to an iPLA₂ β -EGFP fusion protein is not observed in cells transfected with vector containing only the N2 construct (Fig. 1B, lanes 2 and 4), but such a 110- to 115-kDa protein is observed in cells transfected with the vector containing the iPLA₂ β -EGFP construct (Fig. 1B, lanes 1 and 3).

iPLA₂ β enzymatic activity in INS-1 cells overexpressing iPLA₂ β as a fusion protein

To demonstrate that the FPN2-transfected cells express iPLA₂ β enzymatic activity, cytosolic and membrane-associated iPLA₂ β activities were assayed in the absence and presence of ATP or BEL. FPN2-transfected cells were found to express calcium-independent PLA₂ activity in cytosol and membranes nearly four- to fivefold higher than that expressed in N2 cells (data not shown). The calcium-independent PLA₂ activity in FPN2 cells is stimulated by ATP and inhibited by the BEL suicide substrate, as is the case for native iPLA₂ β (3). These findings and those in Fig. 1 demonstrate that transfection of INS-1 cells with the iPLA₂ β -EGFP fusion protein vector causes overexpression of an enzymatically active iPLA₂ β protein.

Amplification of glucose-induced insulin secretion by forskolin

INS-1 cells stably overexpressing iPLA₂ β exhibit greater insulin secretory responses to cAMP-elevating agents in the presence of glucose (3,6). Similarly, when INS-1 cells that overexpress iPLA₂ β as a fusion protein with EGFP are stimulated with the adenylate cyclase

activator forskolin, insulin secretory responses are about threefold higher than those of control cells (data not shown).

Secretagogue-stimulated subcellular redistribution of iPLA₂β

Movements of the iPLA₂β-EGFP were monitored in INS-1 cells transfected with FPN2 vectors after secretagogue stimulation for 0.5–2 h. Under basal conditions, the EGFP fluorescence is dispersed. After addition of glucose and forskolin, punctuate accumulations of green fluorescence appear as a halo around the perinuclear region in the FPN2 cells illustrated in the companion article (10). These findings are analogous to our previous observations where antibodies directed against iPLA₂β were used to visualize localization of iPLA₂β (7).

Secretagogue-stimulated redistribution of iPLA₂β to specific organelles

To determine whether iPLA₂β associates with specific organelles in the cell after stimulation, dual fluorescence analyses using organelle trackers were performed. The targeted organelles were the Golgi apparatus, ER, mitochondria, and plasma membrane. FPN2 cells were treated with glucose and forskolin and then loaded with various organelle-specific trackers. The EGFP (green) and organelle tracker fluorescence signals were then recorded in a field of cells. The individual tracker and EGFP fluorescence signals recorded in FPN2 cells are shown in Fig. 2A and B, respectively, and the overlay of the two recordings is shown in Fig. 2C. As illustrated, green fluorescence associated with the iPLA₂β-EGFP protein appears yellow after overlay with the Golgi-rhodamine fluorescence and as blue-white after overlay with the ER-DAPI (4',6-diamidino-2-phenylindole dihydrochloride) fluorescence. These color changes occur when the two fluorophores colocalize, but not otherwise. There is no apparent overlap of the iPLA₂β-EGFP green fluorescence with the red fluorescence associated with either the mitochondrial or plasma membrane tracker, and the two fluorescent signals remain separate in the overlay image.

DISCUSSION

Many potential biological functions have been proposed for the cytosolic calcium-independent iPLA₂β enzyme (3). Among the proposed functions are its participation in phospholipid remodeling in P388D1 macrophage-like cells (5,11), cell proliferation (12,13), apoptosis (3), and signal transduction in β-cells and in other cells (12).

In β-cells, inhibition of iPLA₂β suppresses glucose-induced insulin secretion, and overexpression of the enzyme enhances secretion, but neither inhibition nor overexpression of iPLA₂β affects incorporation of fatty acids into β-cell phospholipids (12). These findings indicate that iPLA₂β has a signaling role in insulin secretion but does not serve a housekeeping role in phospholipid remodeling in β-cells.

Immunofluorescence analyses using polyclonal antibodies directed against iPLA₂β also indicate that stimulation of β-cells with insulin secretagogues cause redistribution of iPLA₂β within the β-cell. There is accumulation of an iPLA₂β immunofluorescence signal in the perinuclear region of INS-1 insulinoma cells that are stimulated with glucose and the cAMP-elevating agent forskolin (7). To examine this phenomenon further by an approach not confounded by the potential cross-reactivity of iPLA₂β antibodies, iPLA₂β was overexpressed in INS-1 cells as a fusion protein with EGFP in the studies described here. The location of the fusion protein is reflected by green fluorescence associated with EGFP and facilitates tracking of the subcellular location of iPLA₂β.

In INS-1 cells that overexpress iPLA₂β-EGFP, stimulation with glucose alone or in combination with forskolin induces the appearance of punctate accumulations of green

fluorescence as a halo around the perinuclear region. Studies to identify subcellular organelles with which iPLA₂β associates were performed with fluorescent trackers targeted to specific organelles, and these experiments reveal colocalization of iPLA₂β-EGFP-associated green fluorescence with ER and Golgi markers.

Because membranes of the nucleus and ER are contiguous (14,15), perinuclear accumulation of iPLA₂β is consistent with association with a subcellular compartment that is likely to include ER (15). Arachidonate-containing plasmalogen phospholipid molecular species are abundant in β-cell ER and are excellent substrates for iPLA₂β (16). Arachidonic acid and lysophospholipids produced by iPLA₂β-catalyzed hydrolysis of these substrates induce Ca²⁺ release from β-cell ER, which is thought to participate in induction of insulin secretion (16,17). Arachidonic acid hydrolyzed from plasmalogen phospholipid molecular species (18) and/or arachidonate metabolites have been proposed to participate in the β-cell secretory process (17,18), and stimulated association of iPLA₂β with a perinuclear membrane would cause release of arachidonic acid in close proximity to enzymes that catalyze eicosanoid generation and are located in the nuclear envelope and ER (19,20).

Acknowledgments

This research was supported by grants from the National Institutes of Health (R37-DK34388, P41-RR00954, P01-HL57278, P60-DK20579, and P30-DK56341) and by an Award (to S.R.) from the American Diabetes Association.

The authors thank Alan Bohrer and Dr. Mary Wohltmann for expert technical assistance.

Glossary

BEL	bromo-enol lactone
EGFP	enhanced green fluorescent protein
FITC	fluorescein isothiocyanate
iPLA₂β	group VIA cytosolic calcium-independent phospholipase A ₂
PLA₂	phospholipase A ₂

REFERENCES

1. Dennis EA. The growing phospholipase A₂ superfamily of signal transduction enzymes. *Trends Biochem Sci.* 1997; 22:1–2. [PubMed: 9020581]
2. Gijon MA, Spencer DM, Kaiser AL, Leslie CC. Role of phosphorylation sites and the C2 domain in regulation of cytosolic phospholipase A₂. *J Cell Biol.* 1999; 145:1219–1232. [PubMed: 10366595]
3. Ma Z, Turk J. The molecular biology of the group VIA Ca²⁺-independent phospholipase A₂. *Prog Nucleic Acid Res Mol Biol.* 2001; 67:1–33. [PubMed: 11525380]
4. Mancuso DJ, Jenkins CM, Gross RW. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A₂. *J Biol Chem.* 2000; 275:9937–9945. [PubMed: 10744668]
5. Balsinde J, Bianco I, Ackermann E, Conde-Frieboes K, Dennis E. Inhibition of calcium-independent phospholipase A₂ prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. *Proc Natl Acad Sci U S A.* 1995; 92:8527–8531. [PubMed: 7667324]
6. Ramanadham S, Hsu FF, Bohrer A, Ma Z, Turk J. Studies of the role of group VI phospholipase A₂ in fatty acid incorporation, phospholipid remodeling, lysophosphatidylcholine generation, and secretagogue-induced arachidonic acid release in pancreatic islets and insulinoma cells. *J Biol Chem.* 1999; 274:13915–13927. [PubMed: 10318801]

7. Ma Z, Zhang S, Turk J, Ramanadham S. Stimulation of insulin secretion and associated nuclear accumulation of iPLA₂β in INS-1 insulinoma cells. *Am J Physiol Endocrinol Metab.* 2002; 282:E820–E833. [PubMed: 11882502]
8. Hugl SR, White MF, Rhodes CJ. Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent: synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. *J Biol Chem.* 1998; 273:17771–17779. [PubMed: 9651378]
9. Ma Z, Bohrer A, Wohltmann M, Ramanadham S, Hsu FF, Turk J. Studies of phospholipid metabolism, proliferation, and secretion of stably transfected insulinoma cells that overexpress group VIA phospholipase A₂. *Lipids.* 2001; 36:689–700. [PubMed: 11521967]
10. Ramanadham S, Song H, Bao S, Hsu FF, Zhang S, Ma Z, Jin C, Turk J. Islet complex lipids: involvement in group VIA calcium-independent phospholipase A₂-mediated effects in β-cells. *Diabetes.* 2004; 53(Suppl. 1):xxx–xxx.
11. Winstead MV, Balsinde J, Dennis EA. Calcium-independent phospholipase A₂: structure and function. *Biochim Biophys Acta.* 2000; 1488:28–39. [PubMed: 11080674]
12. Ma Z, Ramanadham S, Wohltmann M, Bohrer A, Hsu FF, Turk J. Studies of insulin secretory responses and of arachidonic acid incorporation into phospholipids of stably transfected insulinoma cells that overexpress group VIA phospholipase A₂ (iPLA₂β) indicate a signaling rather than a housekeeping role for iPLA₂β. *J Biol Chem.* 2001; 276:13198–13208. [PubMed: 11278673]
13. Roshak AK, Capper EA, Stevenson C, Eichman C, Marshall LA. Human calcium-independent phospholipase A₂ mediates lymphocyte proliferation. *J Biol Chem.* 2000; 275:35692–35698. [PubMed: 10964913]
14. Matsuura S, Masuda R, Sakai O, Tashiro Y. Immunoelectron microscopy of the outer membrane of rat hepatocyte nuclear envelopes in relation to the rough endoplasmic reticulum. *Cell Struct Funct.* 1983; 8:1–9. [PubMed: 6667511]
15. Schievella AR, Regier MK, Smith WL, Lin LL. Calcium-mediated translocation of cytosolic phospholipase A₂ to the nuclear envelope and endoplasmic reticulum. *J Biol Chem.* 1995; 270:30749–30754. [PubMed: 8530515]
16. Ramanadham S, Bohrer A, Gross RW, Turk J. Mass spectrometric characterization of arachidonate-containing plasmalogens in human pancreatic islets and in rat islet beta-cells and subcellular membranes. *Biochemistry.* 1993; 32:13499–13509. [PubMed: 8257685]
17. Tsunoda Y, Yoshida H, Owyang C. Intracellular control of IP₃-independent Ca²⁺ oscillations in pancreatic acini. *Biochem Biophys Res Commun.* 1996; 222:265–272. [PubMed: 8670194]
18. Turk J, Gross RW, Ramanadham S. Amplification of insulin secretion by lipid messengers. *Diabetes.* 1993; 42:367–374. [PubMed: 8432406]
19. Rollins TE, Smith WL. Subcellular localization of prostaglandin-forming cyclooxygenase in Swiss mouse 3T3 fibroblasts by electron microscopic immunocytochemistry. *J Biol Chem.* 1980; 255:4872–4875. [PubMed: 6768726]
20. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, Smith WL. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. *J Biol Chem.* 1995; 270:10902–10908. [PubMed: 7738031]




FIG. 1. Immunoblotting analyses of expression of the EGFP- iPLA₂β fusion protein in INS-1 cells. Cytosol and membrane protein fractions were prepared, analyzed by SDS-PAGE, and transferred to polyvinylidene difluoride membranes. The membranes were probed with antibodies directed against GFP (*A*) or iPLA₂β (*B*), and the immunoreactive protein bands were visualized by enhanced chemiluminescence. *Lanes 1 and 3:* FPN2 cells; *lanes 2 and 4:* N2 cells.




FIG. 2. Secretagogue-stimulated subcellular redistribution of iPLA₂ β -EGFP (FPN2). The iPLA₂ β -EGFP overexpressing cells (FPN2) were incubated with glucose (2 mmol/l) plus forskolin (2.5 μ mol/l) with organelle trackers for Golgi (5 μ mol/l), ER (600 nmol/l), mitochondria (100 nmol/l), or plasma membrane (0.50 μ mol/l). One hour after stimulation, the EGFP (FITC)-green fluorescent signal was monitored separately from rhodamine-red (Golgi and mitochondrial) and DAPI (4',6-diamidino-2-phenylindole dihydrochloride)-blue (ER) tracker fluorescent signals. *A*: Organelle tracker fluorescence alone. *B*: EGFP fluorescence alone. *C*: Overlay of EGFP and organelle marker fluorescent signals.